Evening Symposia

ES-1 Approaches to exacerbation of COPD
ES-2 New Wind Window in managing COPD
ES-3 Diagnostic and therapeutic approach to pulmonary thromboembolism
ES-4 The Evolution of Asthma Management: Are We Achieving Optimal Control?
ES-5 Respiratory quinolones: Update on management of RTIs
ES-6 Affecting the mortality in COPD: Is the dream becoming a reality?
ES-7 Overview of the cough problem
ES-8 Acute lung injury and role of neutrophil elastase
ES-9 Modern treatment of RTI with moxifloxacin, a new respiratory quinolone

ES-1 Approaches to exacerbation of COPD

This symposium is sponsored by Kyorin Pharmaceutical Co., Ltd and topics will include:

• Overview: Clinical Management of Exacerbation of COPD, presented by John Hurst (Academic Unit of Respiratory Medicine, Royal Free & University College Medical School, London, UK)
• Is a Mucolytic Agent Effective for Management of COPD?, presented by Mutsuo Yamaya (Department of Geriatrics and Gerontology, Tohoku University School of Medicine, Japan)
• Dispatching Data from Asia -PEACE Study in Japan -Therapeutic Option for Exacerbation of COPD, presented by Koichiro Tatsumi (Department of Respirology, Graduate School of Medicine, Chiba University, Japan)
• Dispatching Data from Asia -PEACE Study in China -Therapeutic Option for Exacerbation of COPD, presented by Jian Kang (Institute of Respiratory Disease, China Medical University, China)

(See also COPD Educational Event 2005)

ES-2 New Wind in managing COPD

This symposium is sponsored by Pfizer Japan Inc. and Nippon Boehringer Ingelheim Co., Ltd and topics will include:

• Defining Airflow Limitatation and the Burden of COPD, presented by A. Sonia Buist (Division of Pulmonary & Critical Care Medicine, Oregon Health & Sciences University, USA)
• Update in Managing COPD, presented by Leonardo M. Fabbri (Department of Respiratory Diseases, University of Modena and Reggio Emilia, Italy)
• Rehabilitation of COPD Using Exercise - from Bench to Bedside, presented by Peter D. Wagner (Medicine and Bioengineering in the School of Medicine University of California, USA)

(See also COPD Educational Event 2005)

ES-3 Diagnostic and therapeutic approach to pulmonary thromboembolism

This symposium is sponsored by Eisai Co., Ltd. and topics will include:

• Diagnostic Approach to Acute Pulmonary Thromboembolism, presented by Nobuhiro Tanabe (Department of Respirology, Graduate School of Medicine, Chiba University, Japan)
• Recent Advances in the Treatment for Acute Pulmonary Thromboembolism, presented by Norikazu Yamada (Department of Cardiology, Mie University School of Medicine, Japan)
• Diagnosis and Treatment for Chronic Thromboembolic Pulmonary Hypertention, presented by Shingo Kyotani (The Division of Cardiology and CCU, National Cardiovascular Center, Japan)

ES-4 The Evolution of Asthma Management: Are We Achieving Optimal Control?

This symposium is sponsored by GlaxoSmithKline K.K. and topics will include:

• Aiming for Asthma Control, presented by Andrew Greening (Respiratory Medicine, Western General Hospital, Edinburgh, UK)
• Achieving Optimal Asthma Control, presented by Kenneth R. Chapman (Asthma & Airway Centre, University Health Network, Toronto Western Hospital, Canada)
• Monitoring Asthma Control, presented by Christopher Lai (Department of Medicine and Therapeutics, Division of Respiratory Medicine, The Chinese University of Hong Kong, Hong Kong)

ES-5 Respiratory quinolones: Update on management of RTIs

This symposium is sponsored by Daiichi Pharmaceutical Co., Ltd. and topics will include:

• Driving Forces for Development of Respiratory Quinolones and Recent Efforts , presented by Kazuki Hoshino (Senior Researcher, New Product Research Laboratories I, R & D Center, Daiichi Pharmaceutical Co., Ltd, Japan)
• Recent Trends of Antimicrobiotic-resistant Bacteria in Japan and Asia, presented by Kazuhiro Tateda (Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Japan)
• Current Positioning of Respiratory Quinolone Drugs in Japanese CAP and HAP Guidelines, presented by Kazunori Tomono (Division of Infection Control and Prevention, Osaka University Hospital, Japan)
• The Role of Atypical Pathogens in RTIs, presented by Naoyuki Miyashita (Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, Japan)

*A panel discussion will be held after these presentations.

ES-6 Affecting the mortality in COPD: Is the dream becoming a reality?

This symposium is sponsored by GlaxoSmithKline K.K. and topics will include:

• COPD: A Multi-component Disease, presented by Neil Barnes (London Chest Hospital, UK)
• What Makes a Landmark Trial?, presented by Jørgen Vestbo (University of Manchester, UK and University of Copenhagen, Denmark)
• Can We Help COPD Patients Feel Better and Live Longer?, presented by Peter Calverley (Clinical Service Centre, University Hospital Aintree, UK)
• Is the Dream Becoming a Reality?, presented by Christine Jenkins (Department of Respiratory Medicine, Concord Hospital, Australia)

(See also COPD Educational Event 2005)

ES-7 Chronic cough: pathogenesis and treatment

This symposium is sponsored by Kyorin Pharmaceutical Co., Ltd and topics will include:

• New Approach to Understanding the Pathogenesis of Cough, presented by K. Fan Chung (Respiratory Medicine, National Heart & Lung Institute, Imperial College, UK)
• Eosinophilic Bronchitis and Chronic Cough, presented by Parameswaran Nair (McMaster University, Canada Research Chair in Airway Regulation & inflammation, Firestone Institute for Respiratory Health St.Joseph's Healthcare, Hamilton, Canada)
• Persistent Cough in Nasal and Sinus Diseases, presented by Kensei Naito (Department of Otolaryngology, Fujita Health University, School of Medicine, Aichi, Japan)
• Management of Chronic Persistent Cough, presented by Akio Niimi (Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)

ES-8 Acute Lung Injury and Role of Neutrophil Elastase

This symposium is sponsored by Ono Pharmaceutical Co., Ltd and topics will include:

• Overview, presented by Akitoshi Ishizaka (Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Japan)
• Effects of Neutrophil Elastase Inhibitor in Acute Lung Injury, presented by Satoru Hashimoto (Department of Intensive Care and Anesthesiology, Kyoto Prefectural University of Medicine, Japan)
• Effects of Neutrophil Elastase Inhibitor in Surgical Patients, presented by Yuko Kitagawa (Department of Surgery, Keio University School of Medicine, Japan)

ES-9 Modern treatment of RTI with moxifloxacin, a new respiratory quinolone

This symposium is sponsored by Bayer HealthCare and topics will include:

• The Positioning of Respiratory Quinolones in Japan - Isolated Bacteria from RTI and Sensitivity to Antibiotics, presented by Koichi Izumikawa (Second Department of Internal Medicine, Nagasaki University School of Medicine, Japan)
• The Need for Potent New Drugs in Asia, presented by Po-Ren Hsueh (Departments of Laboratory Medicine and Internal Medicine, College of Medicine, National Taiwan University, Taiwan)
• The Effi cacy of Moxifl oxacin in RTI, presented by Ronald F. Grossman (University of Toronto, Department of Medicine, Credit Valley Hospital, Mississauga, Ontario, Canada)
• Safety of Fluoroquinolones, presented by Peter Ball (School of Biomedical Sciences, University of St. Andrews, UK)

We will discuss the general item of using the best antibiotic directly at first, in this way preventing resistances and costs.

Each session will be last 20 minutes and the symposium will conclude with a 20-30 minute Panel Discussion on using the best antibiotic directly at first, to limit resistance and costs.

(Note: These are not public sessions. Attendance is reserved for those who have registered for the APSR2006 Congress.)